Vitamin B3 Supplement Reduced Occurrences of Basal and Squamous Cell Carcinomas

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dr. Martin discusses the phase III ONTRAC study, which found that the use of nicotinamide, a form of vitamin B3, reduced the incidence of non-melanoma skin cancers by 23% among a group of high-risk patients.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Dr. Martin discusses the phase III ONTRAC study, which found that the use of nicotinamide, a form of vitamin B3, reduced the incidence of non-melanoma skin cancers by 23% among a group of high-risk patients. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. Read our conference report of this study.

      Recent Videos
      microRNA-based Signatures Predict irAEs in Patients Receiving Anti–PD-1 Treatment
      microRNA-based Signatures Predict irAEs in Patients Receiving Anti–PD-1 Treatment
      microRNA-Based Model Predicts SBRT Outcomes in Soft Tissue Sarcomas
      microRNA-Based Model Predicts SBRT Outcomes in Soft Tissue Sarcomas
      New microRNA Models Predict Responses and Toxicities in Various Cancers
      New microRNA Models Predict Responses and Toxicities in Various Cancers
      The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
      Nivolumab May Enhance Outcomes with SOC Therapy for Locally Advanced HNSCC
      Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
      KEYNOTE-689 Results Provide “Foundation” for Alternative HNSCC Strategies
      For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
      Addition of Pembrolizumab to SOC May Enhance HNSCC Cure Rates
      Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
      2025 ASCO Annual Meeting: The Show and After Show
      Assessing Cosibelimab’s Future in Cutaneous Squamous Cell Carcinoma
      Assessing Cosibelimab’s Future in Cutaneous Squamous Cell Carcinoma
      Cosibelimab Shows Promising Efficacy and Safety in Cutaneous CSCC
      Cosibelimab Shows Promising Efficacy and Safety in Cutaneous CSCC
      Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy
      Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy
      Related Content
      Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

      Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

      Tim Cortese
      June 20th 2025
      Article

      Aspirin led to a median disease-free survival of 1.16 years vs 1.35 years with placebo in patients with colorectal cancer liver metastases.

      Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

      Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

      Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
      May 26th 2025
      Podcast

      Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

      A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

      FDA Lifts Hold on IFx-2.0 in Advanced/Metastatic Merkel Cell Carcinoma

      Roman Fabbricatore
      June 9th 2025
      Article

      A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

      Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

      Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

      Neil M. Iyengar, MD;Paolo Tarantino, MD
      June 17th 2024
      Podcast

      Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

      High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

      High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

      Ashling Wahner
      June 5th 2025
      Article

      Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.

      The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

      Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

      Roman Fabbricatore
      June 5th 2025
      Article

      The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.